ASMB

Business Context and Reporting Period

Company: Assembly Biosciences, Inc. (ASMB)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Assembly is a biotechnology company developing therapeutics for serious viral diseases, including recurrent genital herpes (HSV), hepatitis delta virus (HDV), hepatitis B virus (HBV), and transplant-associated herpesviruses. The company has no approved products and relies on collaboration revenue and equity financing to fund operations.

Key Financial Metrics

Debt: The company has no long-term debt. Contractual obligations consist primarily of operating lease liabilities totaling $3.1 million.

Material Changes vs. Prior Period

• Revenue Growth: Collaboration revenue increased 298% to $28.5 million, driven by a full year of revenue recognition under the Gilead Collaboration Agreement (entered in October 2023) and a $10.0 million payment received in December 2024 under the First Amendment to that agreement.
• Reduced Net Loss: Net loss decreased by $21.0 million (34%) compared to 2023, primarily due to higher collaboration revenue and increased interest income ($5.6 million vs. $3.5 million), partially offset by higher R&D expenses.
• R&D Expenses: Increased 14% to $55.9 million. This was driven by external program expenses for advancing HSV candidates (ABI-5366 and ABI-1179) and the HDV candidate (ABI-6250), offset by the discontinuation of the Vebicorvir and ABI-H3733 programs.
• G&A Expenses: Decreased 21% to $18.0 million, largely due to lower legal expenses related to the Gilead deal and reduced stock-based compensation compared to 2023.
• Capital Structure: In December 2024, Gilead exercised an option to purchase additional shares, resulting in Gilead owning 29.9% of the company's outstanding voting common stock. A 1-for-12 reverse stock split was effective in February 2024 to regain Nasdaq compliance.

Guidance, Outlook, and Risks

Outlook and Guidance:

• Cash Runway: Management expects existing cash, cash equivalents, and marketable securities to fund operations into the middle of 2026.
• Clinical Milestones:
  • HSV (ABI-5366 & ABI-1179): Interim Phase 1b data for both candidates expected in Fall 2025.
  • HDV (ABI-6250): Interim Phase 1a data expected in Q3 2025.
  • HBV (ABI-4334): Data from the 400 mg cohort expected in the first half of 2025.

Management Commentary: The company continues to advance its pipeline with positive interim data from Phase 1a studies for its HSV and HBV candidates. The collaboration with Gilead remains a critical component of the business strategy, providing funding and potential commercialization pathways.

Risks and Contingencies:

• Dependence on Gilead: 100% of 2024 revenue came from Gilead. Future funding and commercialization depend on Gilead exercising opt-in rights and the success of the collaboration.
• Capital Needs: The company is not profitable and will require additional financing to complete development. Failure to raise capital could force delays or discontinuation of programs.
• Regulatory Uncertainty: No products are approved; clinical trials may fail to demonstrate safety or efficacy.
• Macroeconomic Factors: Inflation, interest rates, and geopolitical events could impact access to capital.

Key Facts for Investor Verification

• Revenue Concentration: Verify the sustainability of revenue streams given 100% reliance on the Gilead Collaboration Agreement.
• Cash Runway: Confirm the "middle of 2026" liquidity estimate against current burn rates and potential need for dilutive equity raises.
• Clinical Data Timing: Monitor the release of Phase 1b data for ABI-5366 and ABI-1179 in Fall 2025, which are critical for Gilead's potential opt-in decisions.
• Gilead Ownership: Note that Gilead owns 29.9% of the company and has the right to designate two directors, giving them significant influence over corporate governance.
• Deferred Revenue: Review the $73.0 million in deferred revenue (short-term and long-term) to understand the timing of future revenue recognition.